Geographic and Product Information (Tables)

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Schedule of revenues and long-lived assets by geographic area

Revenues	2015		2014		2013
United States	$	5,604.0	$	4,482.8	$	3,862.1
Europe	2,624.3		2,310.8		1,865.7
All other	1,027.7		876.8		766.1
Total revenues	$	9,256.0	$	7,670.4	$	6,493.9

Long-Lived Assets1	2015		2014
United States	$	585.5	$	406.1
Europe	215.2		222.2
All other	13.4		14.3
Total long lived assets	$	814.1	$	642.6

¹  Long-lived assets consist of net property, plant and equipment.

Schedule of total revenues from external customers by product

Total revenues from external customers by product for the years ended December 31, 2015, 2014 and 2013 were as follows:

	2015		2014		2013
REVLIMID®	$	5,801.1	$	4,980.0	$	4,280.3
ABRAXANE®	967.5		848.2		648.9
POMALYST®/IMNOVID®	983.3		679.7		305.4
OTEZLA®	471.7		69.8		—
VIDAZA®	590.7		611.9		803.3
azacitidine for injection	83.9		78.2		23.3
THALOMID®	185.4		221.2		244.5
ISTODAX®	69.1		65.6		54.0
Other	8.4		9.2		2.6
Total net product sales	9,161.1		7,563.8		6,362.3
Other revenue	94.9		106.6		131.6
Total revenue	$	9,256.0	$	7,670.4	$	6,493.9

Schedule of customer concentration risk based on total revenues and net accounts receivable

The percentage of amounts due from these customers compared to total net accounts receivable is also summarized below as of December 31, 2015 and 2014.

	Percent of Total Revenue						Percent of Net Accounts Receivable
Customer	2015		2014		2013		2015		2014
Amerisource Bergen Corp.	8.1	%	9.0	%	10.7	%	8.2	%	9.7	%
CVS	10.7	%	9.8	%	9.3	%	8.2	%	7.6	%